Ayala Pharmaceuticals Inc. (ADXS)
OTCMKTS: ADXS · Delayed Price · USD
0.150
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market open
Company Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers.
The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Ayala Pharmaceuticals Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Dr. Ruth Ben Yakar Ph.D. |
Contact Details
Address: 9 Deer Park Drive, Suite K-1 Monmouth Junction, New Jersey 08852 United States | |
| Phone | 732 545 1590 |
| Website | advaxis.com |
Stock Details
| Ticker Symbol | ADXS |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001100397 |
| CUSIP Number | 007624307 |
| ISIN Number | US0076244062 |
| Employer ID | 84-1521955 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ruth Ben Yakar Ph.D. | Chief Executive Officer |
| Dr. Stela Gangrenovitch Ph.D. | Co-Founder, Chief Scientist Officer and Director |
| Mark Gengrinovitch LLB | Co-Founder, Chief Financial Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 15-12G | Securities registration termination |
| Apr 26, 2024 | 10-K/A | [Amend] Annual report |
| Apr 19, 2024 | 8-K/A | [Amend] Current report |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |